CNBC Pro: Morgan Stanley says this global biotech stock could soar 398% in the next year
Analysts at Morgan Stanley think one global biotech company's stock could soar 398% in the next year. The company's latest regenerative medicine has completed phase 2 trials in Japan and U.S. and is awaiting final approval.
Abbiamo riassunto questa notizia in modo che tu possa leggerla velocemente. Se sei interessato alla notizia puoi leggere il testo completo qui. Leggi di più: